Abstract
Background
Parkinson's disease (PD) is often accompanied by non-motor complications, such as dementia, depression, and psychotic symptoms, which worsen the prognosis and increase the personal and socioeconomic burden of disease. Prevalence estimates of these complications are quite variable and are lacking for the outpatient care sector.
Methods
As part of a larger, nationwide, cross-sectional epidemiological study in n = 315 neurological outpatient settings in Germany, this paper estimates the frequency of dementia and cognitive impairment in n = 873 outpatients meeting the UK Brain Bank criteria for idiopathic PD. Assessments were based on a clinical interview and neuropsychological assessments, including the Hoehn & Yahr rating and Unified Parkinson's Disease Rating Scale (UPDRS). Cognitive impairment was assessed by the Mini-Mental State Exam (MMSE), Clock Drawing Test (CDT) and the Parkinson Neuropsychometric Dementia Assessment (PANDA) and the clinician's diagnosis of dementia was based on the diagnostic criteria of DSMIV.
Results
Using standardized cutoff scores, the prevalence of cognitive impairment in the study sample as measured by various methods was 17.5% by MMSE (≤ 24), 41.8% by CDT (≥ 3), 43.6% by PANDA (≤ 14), and 28.6% met the DSM-IV criteria for dementia. All estimates increased with age and PD severity. Gender was an inconsistent contributor while illness duration had no significant impact on cognition. Multiple regression analyses revealed PD severity to be the strongest predictor of dementia risk (OR = 4.3; 95% CI: 2.1–9.1), while neuropsychiatric syndromes had independent, although modest additional contributions (OR = 2.5, 95% CI: 1.6–3.8).
Conclusion
Estimates of cognitive impairment and dementia in PD patients are largely dependent on the diagnostic measure used. Using established clinical diagnostic standards for dementia the overall rate on routine outpatient neurological care is 28.6%, but using more sensitive neuropsychological measures, rates for cognitive impairment might be up to 2-fold higher. The MMSE revealed strikingly low sensitivity. Neuropsychiatric syndromes, in addition to PD severity and age, have an independent – although modest – additional contribution to patients' risk for cognitive impairment and dementia.
Similar content being viewed by others
References
Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Soerensen P (2003) Prevalence and Characteristics of Dementia in Parkinson's Disease – An 8-Year Prospective Study. Arch Neurol 60:387–392
Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Soerensen P (2001) Risk of dementia in Parkinson's disease: A community-based, prospective study. Neurology 56:730–736
Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, Tandberg E, Cummings J (1999) Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Ps 67:492–496
Adler C (2005) Nonmotor Complications in Parkinson's Disease. Movement Disord 20:S23–S29
American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders – Text revision. American Psychiatric Association, Washington, DC
Campenhausen S, Bornschein B, Wick R, Bötzel K, Sampaio C, Poewe W, Oleson J, Oertel W, Siebert U, Berger K, Dodel R (2005) Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharm 15:473–490
Cormack F, Aarsland D, Ballard C, Tovee M (2004) Pentagon drawing and neuropsychological performance in Dementia with Lewy bodies, Alzheimer's disease, Parkinson's disease and Parkinson's disease with dementia. Int J Geriatr Psych 19:371–377
Efron B, Tibshirani R (1993) An introduction to the bootstrap. Chapman and Hall, London
Emre M (2003) What causes mental dysfunction in Parkinson's disease? Movement Disord 18:63–71
Fahn S (1987) Unified Parkinson's Disease Rating Scale. In: Fahn S, Calne D (eds) Recent Developments in Parkinson's Disease. MacMillan Healthcare Information, Florham Park, NJ, pp 153–163
Folstein M, Folstein S, McHugh P (1975) Mini-Mental state: a practical method for grading the mental state of patients by the clinician. J Psychiatr Res 12:189–198
Hobson P, Meara J (2004) Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Movement Disord 19:1043–1049
Hoehn M, Yahr M (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442
Hughes A, Daniel S, Kilford L, Lees A (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Ps 55:181–184
Hughes T, Ross H, Musa S, Bhattacherjee S, Nathan R, Mindham R, Spokes E (2000) A 10-year-study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 54:1596–1603
Huse D, Schulman K, Orsini L, Castelli- Haley J, Kennedy S, Lenhart G (2005) Burden of illness in Parkinson's disease. Movement Disord 20:1449–1454
Kalbe E, Calabrese P, Kohn N, Hilker R, Riedel O, Wittchen HU, Dodel R, Otto J, Ebersbach G, Kessler J (2007) Screening for cognitive deficits in Parkinson's Disease with the Neuropsychometric Dementia Assessment (PANDA) instrument. Parkinsonism Relat D (in press)
Kalbe E, Riedel O, Kohn N, Dodel R, Calabrese P, Kessler J (2007) Sensitivitat und Spezifitat des "Parkinson Neuropsychometric Dementia Assessment" (PANDA): Ergebnisse der GEPAD-Studie. Aktuel Neurol 34:140–146
Klockgether T (2004) Parkinson's disease: clinical aspects. Cell Tissue Res 318:115–120
Leentjens A, Verhey F, Lousberg R, Spitsbergen H, Wilmink F (2000) The validity of the Hamilton and Montgomery- Asberg Depression Rating Scales as screening and diagnostic tools for depression in Parkinson's disease. Int J Geriatr Psych 15:644–649
Louis E, Schupf N, Manly J, Marder K, Tang M-X, Mayeux R (2005) Association between mild parkinsonian signs in mild cognitive impairment in a community. Neurology 64:1157–1161
Miyasaki J, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, Shulman L, Gronseth G, Weiner WJ (2006) Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Neurology 66:996–1002
Montgomery S, Asberg M (1979) A new depression scale, designed to be sensitive to change. Brit J Psychiat 134:382–389
Muslimovic D, Post B, Speelman J, Schmand B (2005) Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 65:1239–1245
National Institute of Mental Health (1976) CGI: Clinical Global Impressions. National Institute of Mental Health, Chevy Chase, MD
Nishiwaki Y, Breeze E, Smeeth L, Bulpitt C, Peters R, Fletcher A (2004) Validity of the Clock-Drawing-Test as a screening tool for cognitive impairment in the elderly. Am J Epidemiol 160:797–807
Noe E, Marder K, Bell K, Jacobs D, Manly J, Stern Y (2004) Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia. Movement Disord 19:60–67
Riedel O, Dodel R, Spottke A, Deuschl G, Forstl H, Henn F, Heuser I, Oertel W, Reichmann H, Riederer P, Trenkwalder C, Wittchen H-U (2006) Wie beurteilen Arzte die Haufigkeit demenzieller, depressiver und psychotischer Symptome bei Patienten mit der Parkinson- Krankheit? Eine Befragung von 500 Facharzten im ambulanten Versorgungssektor Deutschlands. Aktuel Neurol 33:374–380
Royall RM (1986) Model robust confidence intervals using maximum likelihood estimators. Int Stat Rev 54:221–226
Schrag A, Jahanshahi M, Quinn N (2001) What contributes to depression in Parkinson's disease? Psychol Med 31:65–73
Seigerschmidt E, Mosch E, Siemen M, Forstl H, Bickel H (2002) The clock drawing test and questionable dementia: reliability and validity. Int J Geriatr Ps 17:1048–1054
Shulman K (2000) Clock-drawing: Is it the ideal cognitive screening test? Int J Geriatr Ps 15:548–561
Vingerhoets G, Verleden S, Santens P, Miatton M, De Reuck J (2003) Predictors of cognitive impairment in advanced Parkinson's disease. J Neurol Neurosurg Ps 74:793–796
Wichowicz H, Slawek J, Derejko M, Cubala W (2006) Factors associated with depression in Parkinson's disease: a cross-sectional study in a Polish population. Eur Psychiat 21:516–520
Author information
Authors and Affiliations
Corresponding author
Additional information
The GEPAD study was supported by an unrestricted educational grant of Novartis Pharma GmbH and received support from the German Ministry of Education and Research through award number BMBF No. 01GI9901/1 (R.D.;W.H.O.)
Rights and permissions
About this article
Cite this article
Riedel, O., Klotsche, J., Spottke, A. et al. Cognitive impairment in 873 patients with idiopathic Parkinson's disease. J Neurol 255, 255–264 (2008). https://doi.org/10.1007/s00415-008-0720-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-008-0720-2